BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Onkendi EO, Boostrom SY, Sarr MG, Farnell MB, Nagorney DM, Donohue JH, Kendrick ML, Lombardo KM, Haddock MG, Que FG. Neoadjuvant treatment of duodenal adenocarcinoma: a rescue strategy. J Gastrointest Surg. 2012;16:320-324. [PMID: 21956430 DOI: 10.1007/s11605-011-1667-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CW, Kim M, Fleming JB, Vauthey JN, Katz MH, Lee JE, Conrad C. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol 2017;24:3954-63. [PMID: 28980211 DOI: 10.1245/s10434-017-6098-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jiménez-Fuertes M, Ruíz-Tóvar J, Díaz-García G, Durán-Poveda M. [Moderately differentiated adenocarcinoma of the third duodenal portion]. Cir Cir 2017;85:76-9. [PMID: 26769533 DOI: 10.1016/j.circir.2015.11.005] [Reference Citation Analysis]
3 Mann K, Gilbert T, Cicconi S, Jackson R, Whelan P, Campbell F, Halloran C, Neoptolemos J, Ghaneh P. Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma. Langenbecks Arch Surg 2019;404:439-49. [PMID: 30972486 DOI: 10.1007/s00423-019-01779-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
4 Sista F, Santis GD, Giuliani A, Cecilia EM, Piccione F, Lancione L, Leardi S, Amicucci G. Adenocarcinoma of the third duodenal portion: Case report and review of literature. World J Gastrointest Surg 2012; 4(1): 23-26 [PMID: 22347539 DOI: 10.4240/wjgs.v4.i1.23] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Ynson ML, Senatore F, Dasanu CA. What are the latest pharmacotherapy options for small bowel adenocarcinoma? Expert Opin Pharmacother. 2014;15:745-748. [PMID: 24588646 DOI: 10.1517/14656566.2014.891016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Singh H, Krishnamurthy G, Kumar H, Mandavdhare H, Sharma V, Yadav TD. Surgical Management of Jejunal Tumors: Experience from Tertiary Care Centre. J Gastrointest Cancer 2020;51:901-7. [PMID: 31705396 DOI: 10.1007/s12029-019-00327-5] [Reference Citation Analysis]
7 Shenoy S. Primary small-bowel malignancy: update in tumor biology, markers, and management strategies. J Gastrointest Cancer. 2014;45:421-430. [PMID: 25339426 DOI: 10.1007/s12029-014-9658-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
8 Overman MJ. Rare but real: management of small bowel adenocarcinoma. Am Soc Clin Oncol Educ Book 2013;:189-93. [PMID: 23714497 DOI: 10.14694/EdBook_AM.2013.33.189] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
9 Linden K, Melillo A, Gaughan J, Obinero C, Kellish A, Wozniak MR, Patel RM, Pandya V, Atabek U, Spitz F, Hong YK. The Role of Neoadjuvant Versus Adjuvant Therapy for Duodenal Adenocarcinoma: A National Cancer Database Propensity Score Matched Analysis. Am Surg 2021;87:1066-73. [PMID: 33291951 DOI: 10.1177/0003134820954821] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Wu G, Zhao Q, Li X, Wang M, Sun H, Zhang J, Li Z, Zheng J, Li M, Fan D. Perioperative Complications and Outcomes after Intestinal Autotransplantation for Neoplasms Involving the Superior Mesenteric Artery. J Gastrointest Surg 2020;24:650-8. [PMID: 30937708 DOI: 10.1007/s11605-019-04204-1] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 de Bree E, Rovers KP, Stamatiou D, Souglakos J, Michelakis D, de Hingh IH. The evolving management of small bowel adenocarcinoma. Acta Oncologica 2018;57:712-22. [DOI: 10.1080/0284186x.2018.1433321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
12 Zhang GY, Mao J, Zhao B, Long B, Zhan H, Zhang JQ, Zhou HN, Guo LY, Jiao ZY. Duodenal Bulb Adenocarcinoma Benefitted from Neoadjuvant Chemotherapy: A Case Report. Chemotherapy 2017;62:290-4. [PMID: 28490007 DOI: 10.1159/000469700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Hagihara S, Shimizu T, Inoue Y, Asakuma M, Hirokawa F, Taniguchi K, Hayashi M, Uchiyama K. A complete response to capecitabine and oxaliplatin chemotherapy in primary duodenal carcinoma with liver and nodal metastases: a case report. Surg Case Rep 2018;4:125. [PMID: 30269236 DOI: 10.1186/s40792-018-0532-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
14 Yasuda S, Harada S, Tsujimoto A, Aoki S, Takei T, Migita K, Ueno M, Tatsumi M, Watanabe A. A pathological complete response by chemotherapy with S-1 and oxaliplatin for a locally advanced duodenal adenocarcinoma in Lynch syndrome: a case report. Surg Case Rep 2019;5:146. [PMID: 31637551 DOI: 10.1186/s40792-019-0712-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Kanehira M, Futagawa Y, Furukawa K, Shiba H, Uwagawa T, Yanaga K. Radical resection of a primary unresectable duodenal cancer after chemotherapy using S-1 and cisplatin: report of a case. Surg Case Rep 2017;3:34. [PMID: 28224561 DOI: 10.1186/s40792-017-0304-4] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
16 Lancellotta V, Russo G, Lupattelli M, Iacco M, Perrucci E, Zucchetti C, Falcinelli L, Aristei C. Helical tomotherapy for duodenal adenocarcinoma in an elderly patient: A case report. World J Gastrointest Oncol 2017; 9(2): 94-97 [PMID: 28255431 DOI: 10.4251/wjgo.v9.i2.94] [Reference Citation Analysis]
17 Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013;10:534-544. [PMID: 23897080 DOI: 10.1038/nrclinonc.2013.132] [Cited by in Crossref: 86] [Cited by in F6Publishing: 70] [Article Influence: 9.6] [Reference Citation Analysis]
18 Velandia C, Morales RD, Coello C, Mendoza AG, Pérez G, Aguero E. Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma. Ecancermedicalscience 2018;12:816. [PMID: 29662529 DOI: 10.3332/ecancer.2018.816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Chandrasegaram MD, Chen JW, Price TJ, Zalcberg J, Sjoquist K, Merrett ND. Advances in Molecular Pathology and Treatment of Periampullary Cancers. Pancreas. 2016;45:32-39. [PMID: 26348463 DOI: 10.1097/mpa.0000000000000385] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]